PHYSIOMICS PLC — Regulatory Filings 2014

Aug 14, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1597P

Physiomics PLC

14 August 2014

Physiomics plc

("Physiomics") or ("the Company")

New deal to model immune therapy for cancer with global biopharmaceutical company

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a new contract with a global pharmaceutical company. The project will involve adapting the existing Virtual Tumour to model immunomodulatory agents, currently a significant focus of cancer research. The initial phase of the project will be focused on making pre-clinical predictions. If successful, the project may be extended to also adapt Virtual Tumour Clinical to immune therapies in cancer. The initial project will start immediately and will be completed by the end of 2014.

The project will be performed on a fee-for-service basis.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are extremely pleased to engage with this customer and also to gain our first project targeting immunomodulatory agents. In addition to the revenue generated from this project, Physiomics will benefit greatly from the experience gained building such models in this exciting area of cancer research."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

Communications Portfolio Ltd. (media enquiries)

Ariane Comstive

+44 7785 922 354

ariane.comstive@communications-portfolio.co.uk

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUSRURSKAWAAR